97 related articles for article (PubMed ID: 29025289)
1. [The role of autologous hemopoietic stem cell transplantation in T-cell lymphoma. Hungarian data].
Szomor Á; Csalódi R; Kosztolányi S; Nagy Á; Pammer J; Tóth O; Losonczy H; Alizadeh H; Miltényi Z; Reményi P; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1615-1619. PubMed ID: 29025289
[TBL] [Abstract][Full Text] [Related]
2. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
5. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiology of early infections after autologous hematopoietic stem cell transplantation.
Lakatos B; Szabó H; Csordás K; Tatai G; Nikolova R; Csomor J; Reményi P; Masszi T; Vályi-Nagy I; Sinkó J
Orv Hetil; 2020 Jan; 161(3):103-109. PubMed ID: 31928060
[TBL] [Abstract][Full Text] [Related]
8. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
9. The role of transplantation in Hodgkin lymphoma.
Broccoli A; Zinzani PL
Br J Haematol; 2019 Jan; 184(1):93-104. PubMed ID: 30407612
[TBL] [Abstract][Full Text] [Related]
10. [One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].
Kiss A; Reményi G; Szász R; Batár P; Rejto L; Váróczy L; Sípos T; Kovácsné Kovács E; Szarvas M; Udvardy M
Orv Hetil; 2009 Jul; 150(27):1251-7. PubMed ID: 19531458
[TBL] [Abstract][Full Text] [Related]
11. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
12. [Successful autologous haematopoietic stem cell transplantation in severe, therapy-resistant childhood Crohn's disease. Report on the first case in Hungary].
Kriván G; Szabó D; Kállay K; Benyó G; Kassa C; Sinkó J; Goda V; Arató A; Veres G
Orv Hetil; 2014 May; 155(20):789-92. PubMed ID: 24819188
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Au WY; Lie AK; Siu LL; Chan EC; Ooi GC; Leung AY; Liang R; Kwong YL
Ann Hematol; 2003 Sep; 82(9):548-51. PubMed ID: 14504811
[TBL] [Abstract][Full Text] [Related]
14. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation.
Magyari F; Simon Z; Barna S; Udvardy M; Váróczy L; Illés Á
Hematol Oncol; 2012 Jun; 30(2):98-100. PubMed ID: 22034208
[TBL] [Abstract][Full Text] [Related]
15. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
16. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma.
Al-Toma A; Verbeek WH; Visser OJ; Kuijpers KC; Oudejans JJ; Kluin-Nelemans HC; Mulder CJ; Huijgens PC
Dig Liver Dis; 2007 Jul; 39(7):634-41. PubMed ID: 17531561
[TBL] [Abstract][Full Text] [Related]
17. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
18. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
20. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
